NPCE vs BSX vs MDT vs HOLX

For growth investors, NeuroPace, Inc.

(NPCE) is the stronger pick with 25. 1% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate NeuroPace, Inc. (NPCE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

6x versus Hologic, Inc. at 30. 5x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -27. 7% for Medtronic plc (MDT). Over 10 years, the gap is even starker: BSX returned +155. 5% versus NPCE's -22. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus NeuroPace, Inc. 's 1. 09β — meaning NPCE is approximately 218% more volatile than BSX relative to the S&P 500. On balance sheet safety, Boston Scientific Corporation (BSX) carries a lower debt/equity ratio of 51% versus 4% for NeuroPace, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NeuroPace, Inc.

(NPCE) is pulling ahead at 25. 1% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, NPCE leads at 30. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus -31. 9% for NeuroPace, Inc. — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus -16. 3% for NPCE. At the gross margin level — before operating expenses — NPCE leads at 77. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Medtronic plc (MDT) trades at 14.

1x forward P/E versus 17. 2x for Hologic, Inc. — 3. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.

In this comparison, MDT (3.

6% yield) pays a dividend. NPCE, BSX, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

47), 3. 6% yield). Both have compounded well over 10 years (MDT: +26. 5%, NPCE: -22. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NPCE is a small-cap high-growth stock; BSX is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock; HOLX is a mid-cap quality compounder stock. MDT pays a dividend while NPCE, BSX, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.